173 related articles for article (PubMed ID: 22495381)
1. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy.
Schmidt MT; Himmelfarb EA; Shafi H; Lin F; Xu H; Wang HL
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):478-87. PubMed ID: 22495381
[TBL] [Abstract][Full Text] [Related]
2. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of maspin in distinguishing adenocarcinoma from benign biliary epithelium on endoscopic bile duct biopsy.
Chen L; Huang K; Himmelfarb EA; Zhai J; Lai JP; Lin F; Wang HL
Hum Pathol; 2015 Nov; 46(11):1647-54. PubMed ID: 26362203
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder.
Shi J; Liu H; Wang HL; Prichard JW; Lin F
Hum Pathol; 2013 Apr; 44(4):503-11. PubMed ID: 23079206
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma.
Kawashima H; Itoh A; Ohno E; Miyahara R; Ohmiya N; Tanaka T; Shimoyama Y; Nakamura S; Ebata T; Nagino M; Goto H; Hirooka Y
J Hepatobiliary Pancreat Sci; 2013 Apr; 20(4):441-7. PubMed ID: 23269460
[TBL] [Abstract][Full Text] [Related]
7. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
Hedegaard Jensen G; Mortensen MB; Klöppel G; Nielsen MFB; Nielsen O; Detlefsen S
Pathol Res Pract; 2020 May; 216(5):152925. PubMed ID: 32273198
[TBL] [Abstract][Full Text] [Related]
8. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
Riener MO; Kristiansen G
Hum Pathol; 2011 Sep; 42(9):1368; author reply 1368-9. PubMed ID: 21704356
[No Abstract] [Full Text] [Related]
9. Expression of von Hippel-Lindau gene product (pVHL) and S100P in cystic neoplasms of the pancreas--with an implication for their roles in tumorigenesis.
Liu H; Shi J; Wang HL; Zhang J; Brown RE; Wilkerson M; Lin F
Ann Clin Lab Sci; 2012; 42(2):109-17. PubMed ID: 22585604
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of S100p, IMP3, Maspin, and pVHL in the Differantial Diagnosis of Pancreatic Ductal Adenocarcinoma and Normal/chronic Pancreatitis in Fine Needle Aspiration Biopsy.
Aksoy-Altinboga A; Baglan T; Umudum H; Ceyhan K
J Cytol; 2018; 35(4):247-251. PubMed ID: 30498299
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.
Lin F; Shi J; Liu H; Hull ME; Dupree W; Prichard JW; Brown RE; Zhang J; Wang HL; Schuerch C
Am J Surg Pathol; 2008 Jan; 32(1):78-91. PubMed ID: 18162774
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.
Sasaki M; Sato Y
Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541
[TBL] [Abstract][Full Text] [Related]
14. The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma.
Ezzat NE; Tahoun NS; Ismail YM
J Egypt Natl Canc Inst; 2016 Dec; 28(4):229-234. PubMed ID: 27839709
[TBL] [Abstract][Full Text] [Related]
15. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.
Riener MO; Fritzsche FR; Clavien PA; Pestalozzi BC; Probst-Hensch N; Jochum W; Kristiansen G
Hum Pathol; 2009 Oct; 40(10):1377-83. PubMed ID: 19467694
[TBL] [Abstract][Full Text] [Related]
16. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens.
Keira Y; Takasawa A; Murata M; Nojima M; Takasawa K; Ogino J; Higashiura Y; Sasaki A; Kimura Y; Mizuguchi T; Tanaka S; Hirata K; Sawada N; Hasegawa T
Virchows Arch; 2015 Mar; 466(3):265-77. PubMed ID: 25503275
[TBL] [Abstract][Full Text] [Related]
18. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater.
Kim HG; Park MS; Sung JY; Kim YW; Kim HS; Na K
Anticancer Res; 2019 Sep; 39(9):4947-4955. PubMed ID: 31519600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
